LIFELINE NUTRACEUTICALS, INC.
Contact: Bill Driscoll, President/CEO
info@lifelinenutraceuticals.com
http://www.lifelinenutraceuticals.com
Lifeline Nutraceuticals Develops Co-Factor Formulation for Enhancing
the Body's First Line of Defense against Oxidative Stress
Denver health and nutrition company adapts product strategies to more
quickly market a unique antioxidant therapy that enhances Superoxide
Dismutase, Catalase and Glutathione Peroxidase
DENVER, COLORADO, APR. 12, 2004. Lifeline Nutraceuticals, Inc. (Lifeline)
has focused its efforts to expediently bring a much-needed antioxidant
formulation to market. The formulation has been dubbed, Protandim CF,
and will be marketed within Lifeline's Protandim brand category. The
Protandim brand will eventually contain multiple products that are
specifically designed to enhance the body's primary defense mechanism
against oxidative stress - the three antioxidant enzymes Superoxide
Dismutase (SOD), Catalase (CAT), and Glutathione Peroxidase (GPX.)
Protandim CF is the result of months of extensive research and development
by the company and associated scientists. Originally developed as a "Co-Factor" formulation
to support and complement Lifeline's initial Protandim (CMX-1152) product
candidate (licensed from CereMedix, Inc.), Protandim CF now stands in
its own right as "the better approach" for antioxidant therapy
compared to current category offerings. Due to contractual and developmental
issues/delays/changes with CereMedix, Lifeline has redirected its efforts
to concentrate initially on the Protandim CF product. Talks are occurring
between Lifeline and CereMedix, Inc. regarding the Protandim (CMX-1152)
candidate, but it is now estimated by Lifeline to be perhaps one year
away from commercialization. Protandim CF, on the other hand, can be
available within a few months and includes elements that have shown remarkable
efficacy in positively impacting SOD, CAT and GPX levels.
Protandim CF will be unique in its approach of specifically targeting
SOD, CAT and GPX in multiple areas of the body using a proprietary, patent-pending
blend of botanicals, amino acids and various vitamins and minerals. Independent
studies on the key ingredients have demonstrated the ability of these
elements to enhance the antioxidant enzymes. In conjunction with a recognized
formulation scientist, Lifeline has established a product candidate whose
elements work in conjunction to cooperatively enhance SOD, CAT and GPX
production. With SOD, CAT and GPX enhancement as its sole objective,
Lifeline has determined the best combination of elements and bio-available
forms for maximum enzyme improvement.
Lifeline has established a key partnership in order to expedite the
development and delivery of Protandim CF:
Lifeline has enlisted The Chemins Company (Chemins) of Colorado Springs,
CO to finalize the formulation and produce the product under a contract
manufacturing agreement. Chemins was founded in 1974 by James Cameron,
an industry visionary determined to bring high-quality nutritional products
to consumers. The 200-employee work-force operates in a 300,000 square
foot state-of-the-art facility producing specialty formulas for a wide
range of dietary supplements. Chemins was chosen because of its unparalleled
formulary expertise, dedication to quality assurance, and high-volume
manufacturing capabilities.
Bill Driscoll, President of Lifeline, states that "We are very
encouraged by the involvement of this highly-respected organization as
we look to take Protandim CF through clinical trials and into the marketplace." He
added that "through a lot of hard work and a little chance discovery,
Lifeline now owns a very unique product with quite promising efficacy
and market potential."
Lifeline will also be announcing an additional key appointment to its
management team within the next couple of days.
ABOUT CHEMINS…
Information about The Chemins Company can be found at: http://www.chemins.com
(Hyperlink Disclaimer)
ABOUT LIFELINE NUTRACEUTICALS CORP…
Lifeline is a privately held, Denver-based company formed to manufacture,
market and distribute nutraceutical supplements that promote "Healthy
Life Expectancy." Lifeline is presently focusing exclusively on
unique antioxidant therapies under its Protandim brand. The therapies
center on the body's primary defense mechanism against oxidative stress
- the natural antioxidant enzymes, Superoxide Dismutase (SOD), Catalase
(CAT), and Glutathione Peroxidase (GPX). Discussions have commenced regarding
license agreements and other collaborative arrangements in order to aggressively
place its Protandim product candidates into the global marketplace.
For more information, please contact Bill Driscoll at info@lifelinenutraceuticals.com
Click here for the latest news updates.
Except for historical information contained herein, this document contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 and applicable common law. These statements
involve known and unknown risks and uncertainties that may cause the
Company's actual results or outcomes to be materially different from
those anticipated and discussed herein. Further, the Company operates
in industries where securities values may be volatile and may be influenced
by regulatory and other factors beyond the Company's control. Other important
factors that the Company believes might cause such differences include
the Company's limited cash flow and the rapid development of technology,
lack of liquidity for the Company's common stock, working capital shortages,
the length of time for scientific advances to reach the market (if they
ever reach the market), among other risks. In assessing forward-looking
statements contained herein, readers are urged to carefully read all
cautionary statements contained in the Company's filings with the Securities
and Exchange Commission.
"###"
NOTE: As of 10/26/04, Lifeline Nutraceuticals Corp has been acquired
by Lifeline Therapeutics, Inc.
(OTBB: LFLT).
|